VIRTUAL CONFERENCE
From Gross to Net Estimates and Accruals to Preparing for an IPO to Government Pricing for Biotechs to Revenue Recognition examples and latest updates, this conference will address the latest developments in key areas. You’ll hear from experts at Deloitte, Ernst & Young, CFGI, life science analysts and your industry counterparts.
LEARNING OBJECTIVES:
- Understand the latest accounting changes in key areas
- Recognize the timelines and key factors affecting the life science industry
- Begin to assess the effects of these standards on your company or clients
REGISTRATION INFORMATION:
Cost: $545 (Save $150 off the $695 fee if you sign up by February 12th)
This event will run 8:45-4:40p (EDT) each day.
Register any one of three ways:
1. Register online using a credit card and click the orange button
2. Register by phone at (610) 789-3110
3. Email your contact info to be invoiced to mtarman@acslive.com
| Agenda: DAY 1 | ||
|---|---|---|
| 8:45 | 10:15 | Revenue Recognition Update Cases and examples Interaction of 808 and 606 Evaluating “active participation” Measure of progress SEC comment letter themes ASC 606 Implementation issues and lessons learned in the life science industry |
| 10:15 | 10:30 | Break |
| 10:30 | 11:45 | Preparing for an IPO Accounting considerations Typical steps IPO Trends Unicorns and timing give IPOs a lift Geopolitical and trade issues Outlook |
| 11:45 | 12:30 | Lunch |
| 12:30 | 1:45 | Finance and Accounting Implications of the COVID-19 Crisis Trends in disclosure How COVID is impacting controls and compliance Accounting relief |
| 1:45 | 1:55 | Break |
| 1:55 | 3:15 | Product Launch Considerations Related to US Government Pricing |
| 3:15 | 3:20 | Break |
| 3:20 | 4:40 | Commercial Launches including Gross to Net (GTN) Understanding the Complexities Internal and External Challenges Elements leading to GTN model creation Industry examples and cases |
| Agenda: DAY 2 | ||
|---|---|---|
| 8:45 | 10:10 | SEC & PCAOB Update Comment letter themes MD&A Update Changing regulatory environment Non-GAAP measures ICFR Material weaknesses Cybersecurity disclosures |
| 10:10 | 10:20 | Break |
| 10:20 | 11:30 | Fraud and Cybersecurity in Life Sciences Recent Trends Cases and Examples New threats from COVID Cybersecurity |
| 11:30 | 11:35 | Break |
| 11:35 | 12:45 | Valuation Update Fair Value Accounting Industry Standars for Valuation Models Valuing IPR&D Projects Valuation and Impairment of Intangible Assets |
| 12:45 | 1:30 | Lunch |
| 1:30 | 2:55 | Technology Trends in Life Sciences RPA Data Analytics |
| 2:55 | 3:10 | Break |
| 3:10 | 4:40 | Tax Update R&D Tax Credits Tax Accounting Methods Orphan Drug Credit |
| Conference Series Speakers Include: |
|---|
| Nathan Mitchell Deloitte & Touche, Partner |
| Marcus Lindner Ernst & Young, Senior Manager |
| Kevin Jackson PwC, Director |
| Lindsi Scanlan CFGI, Managing Director |
| Purnima Renjen Deloitte & Touche, IT Director |
| Joseph Segoria Deloitte & Touche, Tax Partner |
| Tom Mantione Ernst & Young, Senior Manager |
| Ryan Dolan CFGI, Partner |
| Melanie Kavanagh CFGI, Managing Director |
| Marcia Deforest Radius
Tax Director |
| Ashley Miranda CFGI
Senior Manager |
| Andrew Trivella Deloitte & Touche, Senior Manager |
| Kelsey Habura Deloitte & Touche, Senior Manager |
| Eliza Biedziak Ernst & Young, Senior Manager |
| Jenny Ciszewski Deloitte & Touche, Partner |
| Serpil Mutlu Tepe Ernst & Young, Manager |
| Alex Althoff Ernst & Young, Senior |
| Whitney Eklund Ernst & Young, Senior Manager |
| Wu Wu Ernst & Young, Senior Manager |
| Mark Marcus Ernst & Young, Senior Manager |
| Kaetlin Liverman Deloitte & Touche, Senior Manager |
| Valerie Vasquez Deloitte & Touche, Partner |